000131214 001__ 131214
000131214 005__ 20240206154529.0
000131214 0247_ $$2doi$$a10.37349/ent.2022.00024
000131214 0248_ $$2sideral$$a130507
000131214 037__ $$aART-2022-130507
000131214 041__ $$aeng
000131214 100__ $$aFernández, Daniel
000131214 245__ $$aEconomics of dry needling and botulinum toxin type A for treatment of post-stroke spasticity: a review
000131214 260__ $$c2022
000131214 5060_ $$aAccess copy available to the general public$$fUnrestricted
000131214 5203_ $$aStroke is one of the most common causes of disability and exerts a high burden of direct and indirect costs. Stroke may cause spasticity, which limits patients’ abilities and affects their activities of daily living, decreasing their quality of life. Conventional treatments are based on physical therapy, anti-spasticity medication, and botulinum toxin type A (BTX-A). However, recently, non-pharmacological approaches have been used, such as dry needling (DN) of myofascial trigger points. BTX-A and DN are two treatments that aim to decrease spasticity in patients with stroke, but their mode of action, application, and costs differ. Thus, there is a need to determine the comparative economics of post-stroke spasticity treatments. For this purpose, a search for all types of cost-effectiveness studies (randomized controlled trials, matched controls, and cohorts) and models of epidemiological data was performed. Studies were selected if they included economic outcomes in stroke patients treated with BTX-A or DN. As a result, 7 studies of BTX-A and 2 of DN were selected. Similarities were found in the outcomes used to assess the effectiveness of both treatments in most studies, with modifications of the Ashworth Scale [Modified Ashworth Scale (MAS)/Modified Modified Ashworth Scale (MMAS)] and quality-adjusted life year (QALY) being the main indicators of effectiveness. However, both the duration of the studies and the evaluation of costs were highly heterogeneous, making comparison difficult. In conclusion, both BTX-A and DN are cost-effective to treat spasticity in patients with stroke, but there is a need for comparative studies to make direct comparisons of cost-effectiveness with the most frequently used outcomes such as the MMAS and QALYs.
000131214 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000131214 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000131214 700__ $$aPujol, Clara
000131214 700__ $$aRuber, Carmen
000131214 700__ $$0(orcid)0000-0002-1674-7788$$aCalvo, Sandra$$uUniversidad de Zaragoza
000131214 700__ $$aLevin, Mindy F.
000131214 700__ $$0(orcid)0000-0002-9201-0120$$aHerrero, Pablo$$uUniversidad de Zaragoza
000131214 700__ $$0(orcid)0000-0002-7876-4735$$aGómez-Trullén, Eva María$$uUniversidad de Zaragoza
000131214 7102_ $$11006$$2245$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Educación Física y Depor.
000131214 7102_ $$11006$$2413$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Fisioterapia
000131214 773__ $$g2 (2022), 131-140$$tExploration of Neuroprotective Therapy$$x2769-6510
000131214 8564_ $$s1544885$$uhttps://zaguan.unizar.es/record/131214/files/texto_completo.pdf$$yVersión publicada
000131214 8564_ $$s2562944$$uhttps://zaguan.unizar.es/record/131214/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000131214 909CO $$ooai:zaguan.unizar.es:131214$$particulos$$pdriver
000131214 951__ $$a2024-02-06-14:51:00
000131214 980__ $$aARTICLE